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Calcium is a second messenger which is required for regulation of many cellular processes. 
However, excessive elevation or prolonged activation of calcium signaling would lead to cell death. 
As such, selectively regulating calcium signaling could be an alternative approach for anti-cancer 
therapy. Recently, we have identified an effective analogue of resveratrol, (Z)3,4,5,4′-trans-
tetramethoxystilbene (TMS) which selectively elevated the intracellular calcium level in gefitinib-
resistant (G-R) non-small-cell lung cancer (NSCLC) cells. TMS exhibited significant inhibitory effect on 
G-R NSCLC cells, but not other NSCLC cells and normal lung epithelial cells. The phosphorylation and 
activation of EGFR were inhibited by TMS in G-R cells. TMS induced caspase-independent apoptosis 
and autophagy by directly binding to SERCA and causing endoplasmic reticulum (ER) stress and 
AMPK activation. Proteomics analysis also further confirmed that mTOR pathway, which is the 
downstream of AMPK, was significantly suppressed by TMS. JNK, the cross-linker of ER stress and 
mTOR pathway was significantly activated by TMS. In addition, the inhibition of JNK activation can 
partially block the effect of TMS. Taken together, TMS showed promising anti-cancer activity by 
mediating calcium signaling pathway and inducing apoptosis as well as autophagy in G-R NSCLC 
cells, providing strategy in designing multi-targeting drug for treating G-R patients.
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Non-small–cell lung cancer (NSCLC) is the most common type of lung cancer which is the leading cause 
of cancer-related death1. Most NSCLC patients are initially responsive to chemotherapy, but drug resist-
ance ultimately occurs and leads to cancer recurrence and poor prognosis2. Molecular targeting therapy 
for lung cancer was first FDA-approved in 2004 which brings new insights and enriches the strategies 
of therapy for lung cancer3. The pioneer example, gefitinib, which is a tyrosine kinase inhibitor (TKI) of 
epidermal growth factor receptor (EGFR), can specifically block the activation of EGFR by binding to 
its ATP binding pocket, resulting in EGFR kinase inhibition4. Patients with EGFR activating mutation 
response well to gefitinib treatment at the beginning, however, further mutation on EGFR or alternative 
pathway would soon emerge within 12 months after the treatment of gefitinib and finally lead to drug 
resistance5. Therefore, novel anti-cancer agents or treatment strategies are deeply required for patients, 
especially for the TKI-resistant patients.
Resveratrol has been demonstrated with multiple promising pharmacological activities for longev-
ity, treatment of heart disease, diabetes and cancer6. Resveratrol is a polyphenol which wildly exists in 
grapes and red wine. The investigation of ‘French Paradox’ which describes improved cardiovascular 
outcomes despite a high-fat diet in French people opens the study of resveratrol in many disorders and 
diseases7–10. It’s anti-cancer effect has been well demonstrated in various types of cancer by regulating 
cell division, growth, angiogenesis and metastasis11. In lung cancer, it has been reported that resveratrol 
induces premature senescence in lung cancer cells (A549 and H460 cells) via induction of NAPDH 
oxidase-5 (Nox5) expression12, resulting in inhibition of proliferation and survival13. However, until now, 
only one analogue of resveratrol, DMU-212 (Chemical structure as shown in Fig.  1a), has been tested 
in the pre-clinical stage for anti-cancer therapy, which has been shown to have very strong anti-cancer 
activity in multiply cancers, like colon14,15 and ovarian cancer16. However, to our knowledge, there is no 
report and investigation of the effect of resveratrol or its derivatives on gefitinib resistant (G-R) NSCLC.
In this study, we have identified an effective resveratrol derivative, TMS, which can selectively inhibit 
the growth of G-R NSCLC cells whereas it is relatively non-toxic to normal lung epithelial cells. Our 
study has demonstrated that TMS is a potential new anti-cancer agent particularly for G-R NSCLC 
patient as it shows selective inhibiting activity on G-R NSCLC. In addition, TMS exhibits anti-cancer 
activity different from resveratrol and DMU-212, which provides a new drug of choice for further ther-
apeutic development.
Results
TMS exhibits selective cytotoxic effect towards G-R NSCLC cells. The effect of TMS on cell 
growth was investigated with four NSCLC cell lines, H1975, H820, A549, H358 and one normal lung 
epithelial cell line (BEAS-2B). Among the four NSCLC cell lines, they have different EGFR genetic muta-
tions, H1975 harbors L858R and T790M double mutation on EGFR, H820 harbors exon 19 in frame 
deletion and T790M double mutation on EGFR, while A549 and H358 have wild-type EGFR. After cul-
turing and treating the cells with a wide concentration of range of TMS for 24 hrs, the viability of cells 
was determined using MTT assay. As shown in Fig. 1b, TMS was more effective in inhibiting the growth 
of G-R (H1975 and H820) NSCLC cells than the other NSCLC cells. Most interestingly, the inhibitory 
effect of TMS on normal lung epithelial cells (BEAS-2B) was the weakest. Even using 10 fold higher 
concentration of the IC50 value of H1975 to treat BEAS-2B, there is still no significant inhibitory effect, 
implying low toxicity of TMS to normal lung epithelium.
Moreover, we have also compared the effect of TMS with DMU-212, which is another documented 
derivative of resveratrol currently on clinical trial, on the same NSCLC cells and normal lung epithelial 
cells. As shown in Fig. 1c, unlike TMS, DMU-212 didn’t show the discriminatory potential in G-R NSCLC 
cells or normal cells and the IC50 values (> 40 μ M) is much higher than that of TMS (57.2 nM). Taken 
together, TMS showed better and more specific inhibition effect on G-R NSCLC cells than DMU-212.
TMS effectively induces caspase-independent apoptosis in G-R NSCLC cells. To investigate 
whether TMS can induce apoptosis in G-R NSCLC cells, we measured apoptosis in H1975 after TMS 
treatment. Firstly, we examined the apoptotic effect of TMS by microscopic and flow cytometric analy-
sis. As shown in Fig. 2a,b, both results revealed that TMS significantly induced apoptosis in H1975. For 
example, in control group, there were less than 10% of cells undergoing apoptosis (Q2+Q3). When cells 
were treated with 40 nM TMS, apoptotic cells increased to 24.65% and in the 60 nM TMS treatment 
group, 33.44% cells were undergoing apoptosis. Moreover, as shown in Fig. 2c, both PARP and caspase-3 
were significantly cleaved and activated by TMS while Bcl-2 was gradually decreased.
To explore whether caspase activation is required for the apoptosis induced by TMS, pan-caspase 
inhibitor Z-VAD-FMK was applied to block caspase activities. Notably, treatment with pan-caspase 
inhibitor failed to block the apoptotic effect of TMS, suggesting that apoptosis induced by TMS is inde-
pendent on caspase activation (Supplementary Figure 1). These results indicated that TMS significantly 
induced apoptosis in G-R cells through caspase-independent pathway.
iTRAQ proteomic analysis demonstrated that mTOR pathway is involved in exerting the spe-
cific toxicity of TMS in G-R NSCLC cells. To identify the potential targets of TMS, protein lysate 
extracted from H1975 cells with or without TMS treatment were compared by iTRAQ labeling proteom-
ics method. After digestion and labeling, proteins were subjected to the automated LC-MS/MS analysis. 
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The information of signals was analyzed by MASCOT search engine and SwissProt 51.6 database. As 
shown in Table 1, when compared with the control group, totally there were 78 proteins down-regulated 
and 75 proteins up-regulated by TMS with more than 1.5 folds difference. To further deciphering the 
related signaling pathway of TMS, the regulated 153 proteins were inputted into Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathway database for bioinformatics analysis. Interestingly, as shown in 
Fig. 2d, twenty-two proteins were involved in key core mechanistic target of rapamycin (mTOR) pathway 
and its downstream ribosome biogenesis pathways. For example, mTOR, S6K, EIF4EBP1 and BSM1 were 
all significantly down-regulated, which suggested that protein synthesis was largely inhibited by TMS in 
H1975 cells.
Figure 1. TMS showed selectivity on G-R NSCLC cells. (a) The chemical structures of resveratrol and 
its two derivatives: (E)3,4,5,4′ -Tetramethoxystilbene (DMU-212) and (Z)3,4,5,4′ -Tetramethoxystilbene 
(TMS). (b) The dose response curve and IC50 value of TMS on NSCLC cell lines and BEAS-2B normal lung 
epithelial cell line. (c) The dose response curve of DMU-212 on NSCLC cells and BEAS-2B cells. Results 
were expressed as mean ± S.E. (*p < 0.05, **p < 0.01, ***p < 0.001).
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Figure 2. TMS significantly induced apoptosis in H1975 and suppressed the mTOR pathway. (a) The 
morphological changes of H1975 cells after treatment of TMS. (b) Flow cytometric analysis of the apoptosis 
level after TMS treatment. Statistical analysis result of b. (c) PARP and caspase-3 were cleaved and activated 
by TMS, while Bcl-2 was downregulated. (d) The result of proteomics showed that mTOR pathway was 
inhibited by TMS. (e) Western-blot result confirmed that TMS selectively inhibited mTOR pathway in G-R 
NSCLC cells H1975 and H820, but no effect on normal lung epithelial cells BEAS-2B. (*p < 0.05, **p < 0.01, 
***p < 0.001).
www.nature.com/scientificreports/
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Protein 
accession Description Treat/Control
KRT84 Keratin, type II cuticular Hb4 OS 0.646
KRT85 Keratin, type II cuticular Hb5 OS 0.654
K2C1 Keratin, type II cytoskeletal 1 OS 0.54
K22E Keratin, type II cytoskeletal 2 epidermal OS 0.629
K2C5 Keratin, type II cytoskeletal 5 OS 0.658
K2C6B Keratin, type II cytoskeletal 6B OS 0.647
K2C75 Keratin, type II cytoskeletal 75 OS 0.656
K2C79 Keratin, type II cytoskeletal 79 OS 0.657
HGFA Hepatocyte growth factor activator OS 0.384
CSN7B COP9 signalosome complex subunit 7b OS 0.408
QTRD1 Queuine tRNA-ribosyltransferase subunit QTRTD1 OS 0.41
HDHD3 Haloacid dehalogenase-like hydrolase domain-containing protein 3 OS 0.412
FUND2 FUN14 domain-containing protein 2 OS 0.437
NPA1P Nucleolar pre-ribosomal-associated protein 1 OS 0.447
VP33A Vacuolar protein sorting-associated protein 33A OS 0.464
RM03 39S ribosomal protein L3, mitochondrial OS 0.473
GLRX2 Glutaredoxin-2, mitochondrial OS 0.475
BMS1 Ribosome biogenesis protein BMS1 homolog OS 0.489
DDI2 Protein DDI1 homolog 2 OS 0.493
BPAEA Bullous pemphigoid antigen 1, isoforms 6/9/10 OS 0.499
IMP4 U3 small nucleolar ribonucleoprotein protein IMP4 OS 0.501
ZN556 Zinc finger protein 556 OS 0.503
SUMO1 Small ubiquitin-related modifier 1 OS 0.526
IASPP RelA-associated inhibitor OS 0.534
APOD Apolipoprotein D OS 0.536
PEPL1 Probable aminopeptidase NPEPL1 OS 0.54
RM16 39S ribosomal protein L16, mitochondrial OS 0.542
YTHD1 YTH domain family protein 1 OS 0.548
VIME Vimentin OS 0.561
THIC Acetyl-CoA acetyltransferase, cytosolic OS 0.564
EDC3 Enhancer of mRNA-decapping protein 3 OS 0.564
RL32 60S ribosomal protein L32 OS 0.57
PSMG3 Proteasome assembly chaperone 3 OS 0.574
DCAF7 DDB1- and CUL4-associated factor 7 OS 0.575
SYLM Probable leucyl-tRNA synthetase, mitochondrial OS 0.578
PEX3 Peroxisomal biogenesis factor 3 OS 0.58
NEC1 Neuroendocrine convertase 1 OS 0.589
CHCH1 Coiled-coil-helix-coiled-coil-helix domain-containing protein 1 OS 0.591
ULA1 NEDD8-activating enzyme E1 regulatory subunit OS 0.591
SH3L1 SH3 domain-binding glutamic acid-rich-like protein OS 0.592
P5CR3 Pyrroline-5-carboxylate reductase 3 OS 0.602
NOC2L Nucleolar complex protein 2 homolog OS 0.609
PCY2 Ethanolamine-phosphate cytidylyltransferase OS 0.61
EXOS7 Exosome complex exonuclease RRP42 OS 0.611
HEAT1 HEAT repeat-containing protein 1 OS 0.611
LCMT1 Leucine carboxyl methyltransferase 1 OS 0.611
TMSL3 Thymosin beta-4-like protein 3 OS 0.612
Continued
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Protein 
accession Description Treat/Control
RCL1 RNA 3~-terminal phosphate cyclase-like protein OS 0.616
NOC4L Nucleolar complex protein 4 homolog OS 0.617
AMPD2 AMP deaminase 2 OS 0.622
TET2 Probable methylcytosine dioxygenase TET2 OS 0.625
BRX1 Ribosome biogenesis protein BRX1 homolog OS 0.626
FRAP Serine/threonine-protein kinase mTOR OS 0.627
ANK3 Ankyrin-3 OS 0.629
ALG13 UDP-N-acetylglucosamine transferase subunit ALG13 homolog OS 0.629
UTP15 U3 small nucleolar RNA-associated protein 15 homolog OS 0.631
CSTF1 Cleavage stimulation factor subunit 1 OS 0.633
CORO7 Coronin-7 OS 0.633
SCAM4 Secretory carrier-associated membrane protein 4 OS 0.633
KI21A Kinesin-like protein KIF21A OS 0.634
EVPL Envoplakin OS 0.635
RRS1 Ribosome biogenesis regulatory protein homolog OS 0.637
NHRF2 Na(+ )/H(+ ) exchange regulatory cofactor NHE-RF2 OS 0.639
PKHD1 Fibrocystin OS 0.644
ZC3H8 Zinc finger CCCH domain-containing protein 8 OS 0.644
PTER Phosphotriesterase-related protein OS 0.646
BL1S3 Biogenesis of lysosome-related organelles complex 1 subunit 3 OS 0.649
CHM4A Charged multivesicular body protein 4a OS 0.65
CP088 Protein C16orf88 OS 0.65
BAX Apoptosis regulator BAX OS 0.651
EIF1A Probable RNA-binding protein EIF1AD OS 0.651
DLRB1 Dynein light chain roadblock-type 1 OS 0.656
NEK9 Serine/threonine-protein kinase Nek9 OS 0.657
PGTA Geranylgeranyl transferase type-2 subunit alpha OS 0.658
TB10A TBC1 domain family member 10A OS 0.662
TPPC5 Trafficking protein particle complex subunit 5 OS 0.663
GMDS GDP-mannose 4,6 dehydratase OS 0.666
BIN1 Myc box-dependent-interacting protein 1 OS 0.666
CO024 UPF0480 protein C15orf24 OS 1.5
PIGS GPI transamidase component PIG-S OS 1.504
SFRIP SFRS2-interacting protein OS 1.507
UROK Urokinase-type plasminogen activator OS 1.509
PRG4 Proteoglycan 4 OS 1.513
CC150 Coiled-coil domain-containing protein 150 OS 1.518
VPRBP Protein VPRBP OS 1.522
CASP Protein CASP OS 1.527
FNTB Protein farnesyltransferase subunit beta OS 1.527
DCLK3 Serine/threonine-protein kinase DCLK3 OS 1.528
RNH2A Ribonuclease H2 subunit A OS 1.531
STK25 Serine/threonine-protein kinase 25 OS 1.532
UB2R1 Ubiquitin-conjugating enzyme E2 R1 OS 1.533
PAI2 Plasminogen activator inhibitor 2 OS 1.543
CUTA Protein CutA OS 1.546
CDK7 Cell division protein kinase 7 OS 1.547
Continued
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Protein 
accession Description Treat/Control
NCOAT Bifunctional protein NCOAT OS 1.548
RT18B 28S ribosomal protein S18b, mitochondrial OS 1.55
K0406 Uncharacterized protein KIAA0406 OS 1.55
CSN6 COP9 signalosome complex subunit 6 OS 1.551
CA050 Uncharacterized protein C1orf50 OS 1.563
TBCD Tubulin-specific chaperone D OS 1.582
CP055 Uncharacterized protein C16orf55 OS 1.582
MAVS Mitochondrial antiviral-signaling protein OS 1.59
JAK3 Tyrosine-protein kinase JAK3 OS 1.593
RPB1B DNA-directed RNA polymerase II subunit RPB11-b1 OS 1.596
GNL1 Guanine nucleotide-binding protein-like 1 OS 1.6
OPRS1 Sigma 1-type opioid receptor OS 1.611
DNJC5 DnaJ homolog subfamily C member 5 OS 1.631
ECSIT Evolutionarily conserved signaling intermediate in Toll pathway, mitochondrial OS 1.633
CE033 UPF0465 protein C5orf33 OS 1.634
ITPA Inosine triphosphate pyrophosphatase OS 1.635
ARL1 ADP-ribosylation factor-like protein 1 OS 1.637
T2AG Transcription initiation factor IIA subunit 2 OS 1.638
NEUL Neurolysin, mitochondrial OS 1.65
RB3GP Rab3 GTPase-activating protein catalytic subunit OS 1.667
VGF Neurosecretory protein VGF OS 1.67
NUDC2 NudC domain-containing protein 2 OS 1.671
CCD12 Coiled-coil domain-containing protein 12 OS 1.683
ENL Protein ENL OS 1.687
RASF9 Ras association domain-containing protein 9 OS 1.691
ABR Active breakpoint cluster region-related protein OS 1.712
NDUB1 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 1 OS 1.718
PAG1 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 OS 1.749
PLMN Plasminogen OS = Homo sapiens GN = PLG PE = 1 SV = 2 1.766
RAB23 Ras-related protein Rab-23 OS 1.778
OASL 59 kDa 2 ~ − 5 ~ − oligoadenylate synthetase-like protein OS 1.8
GOLI4 Golgi integral membrane protein 4 OS 1.842
RM42 39S ribosomal protein L42, mitochondrial OS 1.847
SFXN4 Sideroflexin-4 OS 1.867
UAP1L UDP-N-acetylhexosamine pyrophosphorylase-like protein 1 OS 1.872
RMD3 Regulator of microtubule dynamics protein 3 OS 1.892
FA21A WASH complex subunit FAM21A OS 1.892
CC121 Coiled-coil domain-containing protein 121 OS 1.896
GRLF1 Glucocorticoid receptor DNA-binding factor 1 OS 1.896
MK07 Mitogen-activated protein kinase 7 OS 1.896
ZN408 Zinc finger protein 408 OS 1.896
HPS5 Hermansky-Pudlak syndrome 5 protein OS 1.918
SCOT1 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial OS 1.944
SNF5 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 OS 1.97
RFIP5 Rab11 family-interacting protein 5 OS 1.974
Continued
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To confirm the results of proteomics, we examined the effect of TMS on the expression level of the 
key members in the mTOR pathway. Figure 2e showed that both upstream and downstream members 
of mTOR pathway, such as AKT, P70S6 kinase and S6 kinase, were all significantly inhibited by TMS 
in both H1975 and H820 cells but not in normal lung BEAS-2B epithelial cells. Overall, the results of 
proteomics and western blot confirmed that mTOR pathway was involved in mediating the anti-cancer 
effect of TMS.
TMS induces apoptosis and suppresses mTOR pathway by significantly increasing the cellu-
lar calcium level. To explore the upstream mechanism of TMS that drove the effect of induction of 
apoptosis and suppression of the mTOR pathway, firstly we measured the reactive oxygen species (ROS) 
levels. However, no significant change in ROS was observed (Supplementary Figure 2), which suggested 
that oxidative stress was not involved in mediating TMS action. Since mTOR could be mediated by 
Ca2+/Calmodulin-dependent Protein Kinase Kinase (CaMKK)-AMPK pathway17, so we next examined 
whether TMS regulated calcium signaling. To investigate whether TMS can enhance cytosolic [Ca2+] 
level, H1975 cells were stained with Fluo 3-AM to monitor and compare the cellular [Ca2+] level. The 
results of Fig. 3a demonstrated that H1975 cells displayed a remarkable increase in Fluo 3-AM fluores-
cence intensity upon TMS treatment right after 2 hrs.
Sarcoplasmic/endoplasmic reticulum (SERCA) is the main calcium pump that reduces the cytosol 
[Ca2+] by transferring the [Ca2+] to the lumen of the ER. In our study, molecular docking was carried out 
to explore the binding affinity of TMS with SERCA. Based on the docking score, the pose with the lowest 
one was selected as the most probable binding pose of TMS in SERCA. Figure 3b(A,C) illustrated that 
TMS could be docked into the SERCA TG binding site. The hydrophobic groups of TMS bind deeply into 
the hydrophobic pocket of SERCA and have favorable hydrophobic and van der Waals interactions with 
residues Phe256, Ile765, Ile829, Phe834 and et al. Compounds DMU-212 and TMS are cis-trans-isomers. 
However, TMS showed better and more specific inhibition effect on G-R NSCLC cells than DMU-212. 
To explain the reason behind this difference, we quantitatively evaluated the contribution of each residue 
in SERCA for TMS and DMU-212 binding and also studied the binding mode of DMU-212 to SERCA 
by molecular dynamics simulations. As illustrated in Fig. 3b(C,D), there were 13 and 14 residues identi-
fied as key ones (with the absolute energy contribution ≥ 0.5 kcal/mol) for binding TMS and DMU-212 
respectively. However, binding free energy contributions of the key residues to TMS and DMU-212 are 
much different, which may be the origins for their different inhibition effect.
The stability of the simulation systems were assessed by the plot of structural root mean square devia-
tion (RMSD) of protein backbone atoms versus time (supplementary Figure 3). The binding free energies 
of SERCA in complex with TMS and DMU-212 were calculated and the results (∆G_(MM/GBSA)) were 
− 39.41 and − 38.21 kcal/mol respectively, which is consistent well with the experimental results that 
TMS showed better and more specific inhibition effect than DMU-212.
Moreover, the enzyme activity of SERCA was investigated after treatment of TMS. Attractively, TMS 
can significantly suppress the activity of SERCA without changing SERCA expression level (supplemen-
tary Figure 4 and 5a). Therefore, from this part of result, it is clear that TMS can directly interact with 
SERCA and thus inhibit its activity.
Protein 
accession Description Treat/Control
CTGF Connective tissue growth factor OS 2.085
NACA2 Nascent polypeptide-associated complex subunit alpha-2 OS 2.101
CE022 UPF0489 protein C5orf22 OS 2.115
T2H2L General transcription factor IIH subunit 2-like protein OS 2.149
SNX9 Sorting nexin-9 OS 2.247
CLP1L Cleft lip and palate transmembrane protein 1-like protein OS 2.276
PPIC Peptidyl-prolyl cis-trans isomerase C OS 2.329
PSME4 Proteasome activator complex subunit 4 OS 2.347
RRP7A Ribosomal RNA-processing protein 7 homolog A OS 2.422
RUSD2 RNA pseudouridylate synthase domain-containing protein 2 OS 2.504
S7A6O Protein SLC7A6OS OS 3.013
DCTN6 Dynactin subunit 6 OS 3.233
IBP5 Insulin-like growth factor-binding protein 5 OS 4.22
APOC2 Apolipoprotein C-II OS 4.812
Table 1.  The results of proteomics analysis.
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To ascertain whether the increase of [Ca2+] levels plays an important role in TMS-induced cell death, 
Ca2+ chelator (BAPTA/AM, BM) and specific inhibitor of the CaMKK-β (STO-609) were applied to 
co-treat with TMS. Interestingly, Fig.  3c,d showed that both BM and STO-609 remarkably relieved 
Figure 3. TMS regulated the [Ca2+] level in H1975 by directly targeting SERCA and inhibited the 
growth of cells. (a) TMS significantly elevated the [Ca2+] level after 2 hours treatment. (b) Modeling of the 
TMS and DMU-212 bound to the SERCA. Binding mode and per-residue interaction energy of SERCA with 
TMS (A,C) and DMU-212 (B,D) were presented. Residues with the absolute energy contribution ≥ 0.5 kcal/
mol are shown. (c) TMS significantly induced the ROS generation in H1975. (d) The increase of intracellular 
[Ca2+] level was required for TMS to inhibit the growth of H1975 cells. Calcium chelator (BM) and 
CaMKKβ inhibitor (STO-609) remarkably inhibited the apoptosis induced by TMS. (*p < 0.05, **p < 0.01, 
***p < 0.001).
www.nature.com/scientificreports/
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the apoptosis induced by TMS. These results suggested that the increase of [Ca2+] level is required for 
TMS-induced apoptosis and suppressing the mTOR pathway.
TMS induces endoplasmic reticulum (ER) stress in G-R NSCLC cells. Calcium is essential for 
the activation and growth of cells, whereas overloading or prolonged cytosolic calcium elevation will 
lead to cells dysfunction and death, for example ER stress, autophagy and apoptosis in G-R NSCLC is 
yet unknown18. Since TMS can remarkably enhance the cytosolic [Ca2+] level, we further determined 
whether TMS can induce ER stress in H1975. As shown in Fig. 4a, the key members of ER stress pathway, 
PERK, eIF2α were activated and CHOP was upregulated by TMS. The result suggested that TMS signif-
icantly induced ER stress in H1975. Then, we used BM to ascertain whether the ER stress induced by 
TMS is due to the increase of [Ca2+] level. In Fig. 4b, co-treatment of BM or STO-609 with TMS almost 
Figure 4. TMS induced ER stress in H1975 by mediating Ca2+ level. (a) TMS activated ER stress pathway. 
(b,c) BM and STO-609 greatly counteracted the effect of TMS on cell growth, mTOR pathway, and ER stress. 
(*p < 0.05, **p < 0.01, ***p < 0.001).
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completely blocked the effect of TMS on ER stress. Moreover, the inhibition effect of TMS on the mTOR 
pathway and cell growth was also counteracted by BM. Similar result was also obtained by co-treatment 
with STO-609 and TMS as shown in Fig. 4c.
TMS induces AMPK activation and autophagy in G-R NSCLC cells. It is well-known that one 
of the important AMPK activation mechanism is by induction of calcium influx which could phospho-
rylate CaMKK-β and thus activate AMPK19. In Fig.  5a, TMS significantly induced the phosphoryla-
tion of AMPK as well as its direct downstream target acetyl-CoA carboxylase (ACC). Since AMPK is a 
major upstream regulator of mTOR, the activation of AMPK is able to suppress the activity of mTOR20. 
Therefore, we applied compound C which is a specific inhibitor of AMPK to block the activation of 
AMPK and further investigate whether it can activate mTOR and offset the effect of TMS. As shown in 
Fig. 5b–d, compound C partially recovered the inhibition effect of TMS on P70S6K which is the direct 
target of mTOR-mediated apoptosis and cell death.
In addition, activating the signaling cascade of CaMMKK-β -AMPK-mTOR can lead to autophagy17. 
In addition, autophagy is directly involved in reducing the growth of tumor cells21, thus, chemical auto-
phagy inducers could have the potential of inhibiting tumor growth22. We used immunofluorescence 
to detect the LC3-II formation which is an essential protein of the autophagosome for further demon-
strating if TMS induces autophagy. As shown in Fig.  5e,f, endogenous LC3-II showed a significantly 
increase of puncta formation in cells treated with TMS. However, this effect wasn’t observed in normal 
lung epithelial cells BEAS-2B (supplementary Figure 5b). On the other hand, autophagic flux can be 
monitored by measuring the turnover of LC3-II in the presence or absence of lysosomal inhibitors. 
Prevention of lysosomal degradation can be achieved through the use of protease inhibitors23. Thus, we 
determined the conversion of LC3-II by western blot in the presence of lysosomal protease inhibitors 
(bafilomycin A1)23. As expected, TMS markedly increased the rate of LC3-II formation in the presence 
of the inhibitors when compared with the use of either inhibitors or TMS treatment alone, suggesting 
that TMS induces autophagic activity due to enhanced autophagosome formation. Taken together, the 
above results suggested that TMS remarkably induced AMPK activation and autophagy in H1975 cells.
JNK is involved in TMS-induced cell death. It has been reported that c-Jun N-terminal kinases 
(JNK) is closely associated with ER stress and mTOR pathway24. To investigate whether JNK was also 
involved in the anti-cancer mechanism of TMS, we examined the activation of JNK with the treatment 
of TMS. In Fig. 6a, JNK was significantly activated by TMS. To determine whether the activation of JNK 
was required for TMS to induce cell death, JNK specific inhibitor SP600125 was used to inhibit the acti-
vation of JNK. Interestingly, as shown in Fig. 6b–e, the apoptosis and cell death induced by TMS were 
all partially rescued by JNK inhibitor. The inhibition on P70S6 kinase which is the direct downstream 
target of mTOR, was also largely blocked by it. These results indicated that the activation of JNK played 
an important role in TMS-induced cell death in gefinitib-resistant NSCLC cells.
TMS inhibits the activation of EGFR pathway. It is well-known that G-R NSCLC cells are largely 
dependent on constitutively active EGFR pathway. Activation of EGFR would stimulate its downstream 
kinases including PI3K, Akt, and mTOR25, and thus enhance and prolong cancer cells growth and sur-
vival. Since TMS showed discriminatory effect on G-R NSCLC cells, we investigated whether it is due 
to the inhibitory effect on EGFR. As shown in Fig.  7a, TMS largely inhibited the phosphorylation of 
EGFR on 1173 sites in two G-R NSCLC cells (H1975 and H820). Moreover, the downstream targets of 
EGFR, such as PI3K and ERK (as shown in Fig. 7c), were inhibited by TMS either. However, as shown in 
Fig. 7b, there was no significant change in both EGFR wild-type cell lines:A549 and H358; and normal 
lung epithelial cell line (BEAS-2B), suggesting selectively of TMS on EGFR activity across G-R NSCLC 
cells and EGFR wild-type cells.
To ascertain whether the inhibition of TMS on EGFR activation was mediated through the increase 
of intracellular calcium level, we used BM to co-treat with TMS. In Fig. 7d, BM remarkably relieved the 
inhibitory effect of TMS on EGFR, which indicated that the inhibition on EGFR activation by TMS is 
also regulated by calcium. Taken together, TMS can significantly suppress the activity of EGFR which is 
required for the G-R NSCLC cells for survival and growth; and contributes to the discriminatory effect 
of TMS.
Discussion
Drug resistance is a Gordian knot in chemotherapy, which largely decreases the efficacy of drug treat-
ment outcomes on patients. There are various mechanistic for inducing acquired resistance, for example, 
genetic mutation26, multi-drug resistant (MDR) genes overexpression27 and alternative pathway activa-
tion28. For G-R NSCLC patients, nearly 49% of the resistance cases are due to the presence of T790M 
second mutation on EGFR. Although second generation TKI has been developed, which can inhibit 
activation of EGFR with T790M mutation29. However, further acquired resistance is still unavoidably 
happened after prolong usage of these TKIs30. Therefore, developing novel targets for anti-cancer therapy, 
especially for G-R patients, as well as developing novel multi-targeting therapeutic strategy is urgently 
required.
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In this study, we have firstly identified an effective agent, TMS which can effectively and specifically 
induce cell death in G-R NSCLC cells, whereas it is non-toxic to normal lung epithelial cells. When 
compared with another derivative of resveratrol, DMU-212, with IC50 value which falls to micro-molar 
level, TMS has IC50 value at nano-molar level and thus it is more effective than DMU-212. Also, only 
TMS but not DMU-212 has selectivity on G-R NSCLC cells, making it more promising with a wider 
therapeutic window between tumor with EGFR mutation and normal lung tissue with wild-type EGFR.
Figure 5. TMS activated AMPK pathway and induced autophagy in H1975. (a) TMS increased the 
phosphorylation of AMPK and its downstream target ACC. (b,c) Inhibition of AMPK by compound c can 
partially rescue the cells from apoptosis. (d) The statistical result of (c). (e) TMS induced autophagic LC3 
puncta formation in H1975. (f) TMS induced autophagic flux in H1975 cells. Cells were treated with TMS 
(60 nM) in the presence or absence of 50 nM lysosomal protease inhibitors, bafilomycin A1 for 24 h. Cell 
lysates were analyzed by western blot for LC3-II conversion. (*p < 0.05, **p < 0.01, ***p < 0.001).
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The main anti-cancer mechanism of TMS is due to regulation of calcium signaling. From our study, 
TMS can directly bind to SERCA and significantly increase the intracellular [Ca2+] level and further 
mediate downstream calcium signaling cascades. It has been reported that the activation of EGFR stimu-
lated cellular calcium signaling and promoted the growth of cancer cells31. However, whether overloading 
[Ca2+] has negative feedback effect on EGFR is unknown. Interestingly, our study demonstrated that in 
G-R H1975 cells, elevation of [Ca2+] resulting in inhibiting of EGFR at tyrosine 1173 site, causing onco-
genic shock and apoptosis in EGFR-dependent cells like H1975 and H820 but not for EGFR-independent 
Figure 6. JNK activation was involved in TMS induced cell death. (a) TMS activated JNK. (b) MTT assay 
showed that JNK inhibitor blocked the cell death induced by TMS. (c) Inhibiting JNK activation can rescue 
the suppression of TMS on mTOR pathway. (d–f) Blocking the activation of JNK can greatly inhibit the 
apoptosis induced by TMS. (g) The activation of JNK was regulated by TMS through mediating [Ca2+] level. 
(*p < 0.05, **p < 0.01, ***p < 0.001).
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cell line such as A549 and H358. Here, we reported at the first time, the discriminatory effect of TMS to 
G-R NSCLC cells could be caused by negatively feedback regulation of EGFR activation after triggering 
overloaded [Ca2+] influx.
As shown in Fig. 7e, after increasing the intracellular [Ca2+] level, TMS consequently caused activa-
tion of two signaling pathways, the ER stress and the CaMKK-β -AMPK- mTOR pathway. TMS signifi-
cantly induced the ER stress and then apoptosis by increasing cellular [Ca2+] level. Moreover, ER stress 
triggered apoptosis through inducing JNK activation, using JNK inhibitor SP600125 largely counteracted 
the effect of TMS.
Figure 7. TMS inhibited EGFR activation by regulating [Ca2+] level. (a) TMS specifically inhibited the 
phosphorylation of tyrosine residue 1173 on EGFR in G-R NSCLC cells. (b) TMS has no effect on EGFR 
in EGFR wild-type NSCLC cells: A549 and H358 and normal lung epithelial cells BEAS-2B. (c) TMS also 
inhibited the activation of EGFR downstream pathways. (d) The proposed framework of TMS action on 
H1975 cells.
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The result of iTRAQ proteomics also showed that TMS remarkably inhibited the CaMKKβ -AMPK- 
mTOR pathway. Noted that the main members of this pathway includes AKT, mTOR, P70S6K and S632,33 
which were all significantly down-regulated after TMS treatment. The mTOR signaling pathway senses 
and integrates a variety of environmental cues to regulate organismal growth and homeostasis34. It has 
been reported that mTOR pathway could be activated by the stimulus like growth factor, insulin and also 
sensing cellular nutrient, such as oxygen, and energy levels35–37. The major targets of mTOR appear to 
be transcriptional factors and components of the translation machinery38. Therefore, mTOR can directly 
regulate RNA transcription and translation, thus controlling cell growth and proliferation. Since mTOR 
is a kinase that functions as a master switch between catabolic and anabolic metabolism, it has become 
a hot target for the design of new anticancer agent39. Rapamycin is currently the most well-established 
mTOR inhibitors40. However, long-lasting objective tumor response was only shown in clinical trials, 
with CCI-779 being a first-in-class mTOR inhibitor that improved the survival of patients with advanced 
renal cell carcinoma in clinic39. All of these evidences further support that TMS has potential to be 
further explored in vivo and in clinics due to its strong efficacy in G-R resistant cells and converging 
inhibition effect on the mTOR pathway.
In sum, our study has provided new information of the potential use of a new resveratrol derivative 
TMS for treating G-R NSCLC patients. Since the anti-cancer mechanism of TMS is different from that 
of current EGFR TKIs, by not only directly targeting EGFR but exerting multi-targeting effect on EGFR 
as well as crosstalk pathways. Thus single use of TMS or combination use of TMS with TKIs may be 
beneficial to G-R NSCLC patients.
Materials and Methods
Materials. All chemicals and reagents were purchased from Sigma (St Louis, MO, USA) unless oth-
erwise stated. Bafilomycin A1 was obtained from Calbiochem (San Diego, CA). TMS was purchased 
from ‘Great Forest Biomedical Ltd’, and the purity was confirmed with our HPLC analysis. TMS was 
dissolved in dimethyl sulfoxide (DMSO) to form a 100 mM stock solution, fetal bovine serum (FBS), 
antibiotics and RPMI medium were purchased from Gibco (Carlsbad, CA, USA). BEBM medium was 
purchased from Lonza (Allendale, NJ, US). RIPA lysis buffer and antibodies anti-LC3B, anti-PARP, 
anti-p-EGFR(Tyr845/1068/1173), anti-cleaved caspase-3 (Asp175), anti-p-extracellular signal-regulated 
kinase 1/2 (Erk1/2) (Thr202/Tyr204), anti-p-Akt (Ser473), anti-ribosomal protein S6 kinase (p70S6K) 
(Thr389), anti-PI3K, anti-JNK, anti-Erk1/2, anti-Akt, anti-p70S6K anti-S6 kinase, anti-PERK, anti-
Bcl-2, and anti-EGFR were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies 
anti-p-eIF2α , anti-eIF2α , anti-CHOP, anti-GAPDH and anti-SERCA were purchased from Santa Cruz 
(Dallas, Texas, TX, USA). Fluorescence-conjugated secondary antibodies were purchased from Odyssey 
(Lincoln, NE, USA). The ZyMax™ TRITC-conjugated anti-mouse secondary antibodies were purchased 
from Invitrogen (Scotland, UK).
Cell culture. A549 and H1975 NSCLC cells were all purchased from ATCC. Cells were cultured in 
RPMI1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 μ g/ml streptomycin. The 
culture flasks of BEAS-2B were pre-coated with a mixture of 0.01 mg/ml fibronectin, 0.03 mg/ml bovine 
collagen type I and 0.01 mg/ml bovine serum albumin dissolved in BEBM medium (Lonza, Allendale, 
NJ, US). All the cells were cultivated at 37 °C with 5% CO2 incubator.
Cell viability assay. Cells were plated in 96-well plates. After treatment of various doses of TMS for 
24 h, cells viability was determined by MTT assay as described. The viability (%) was expressed as = [OD 
of treated group/OD of control group] × 100%. The viability of the control group was considered as 
100%.
Apoptosis analysis by flow cytometer. A hundred thousand cells were seeded in each well of 
6-well plates and cultured overnight for adhesion. Next day, they were treated with a series dose of 
TMS for 24 h. After treatment, cells were double-stained with PI and Annexin V for 15 min. Finally, the 
percentage of apoptotic cells was analyzed by a flow cytometer (BD FACSAria III, BD, Franklin Lakes, 
NJ, USA).
Western blot analysis. After treatment, cells were lysed in RIPA lysis buffer containing protease 
inhibitor cocktail for 15 min on ice and then boiled for 3 min. The protein concentration was determined 
with a Bio-Rad DCTM Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Thirty μ g protein lysate were 
loaded and separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose 
(NC) membrane. The membranes were incubated with the primary antibody (1:2000) and then with a 
fluorescence-conjugated secondary antibody (1:10000). GAPDH was used as the loading control and 
for normalisation. The signal of the membranes was scanned with a LI-COR Odyssey Scanner (Belfast, 
ME, USA).
iTRAQ proteomics. Cells lysate was centrifuged at 12,000 g for 5 mins at 4 °C. The supernatant was 
processed with ice-cold acetone and re-suspended in the dissolution buffer provided in iTRAQ Reagent 
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4-Plex kit (AB SCIEX, Framingham, MA, USA). The concentration of protein samples was determined 
by 2-D Quant Kit (GE, Fairfield, Connecticut, USA) and adjusted to 5 μ g/μ L.
iTRAQ labeling was carried out following the manufacturer’s protocol of iTRAQ Reagent 4-Plex kit. 
Briefly, the lysates were reduced with reducing reagent, alkylated with cysteine blocking reagent and 
digested with a trypsin to protein ratio of 1:10 (w/w) at 37 °C for 16 hr. Peptides of control group were 
labeled with iTRAQ reagent 116 and that of treated cells were labeled with iTRAQ reagent 117. Both 
samples were combined and the samples were desalted using Sep-Pak C18 cartridge (Waters, Milford, 
Massachusetts, USA) and then purified using a strong cation exchange (SCX)-cartridge (Phenomenex, 
Torrance, California, USA). The peptide sample was then applied to 24 cm pH 3.9–5.1 IPG strips for isoe-
lectric focusing and then the IPG strips were cut into 24 equal fractions. Peptides from IPG strip frac-
tions were extracted with a gradient solution (sequential extractions with 0.1% TFA, 50% ACN/0.1%TFA 
and 100% ACN/0.1% TFA). The solution of each step was vacuum dried and cleaned up by OASIS HLB 
cartridge (Waters, Milford, Massachusetts, USA) and eluted with 70% ACN/0.1% TFA twice. Eluates were 
dried under vacuum and reconstituted in 25 μ L of 2% ACN/0.1% TFA before 1D-LC-MS/MS analysis.
Approximately 0.2 μ g of peptides were subjected to the automated LC-MS/MS analysis, using Dionex 
Ultimate 3000 RSLC system coupled on-line to Bruker maXis Impact Q-TOF MS. MS/MS data was 
processed using Bruker Compass Data Analysis software, and the generated peak lists were submitted to 
MASCOT search engine against SwissProt 51.6 database.
Computational docking. The initial structure of TMS and DMU-212 was downloaded from the 
PubChem (http://pubchem.ncbi.nlm.nih.gov). TMS structure was processed by the LigPrep (Version 2.3, 
Schrödinger, LLC, New York, NY) based on OPLS-2005 force field41. The ionized state was assigned 
by using Epik (Version 2.0, Schrödinger, LLC, New York, NY) at a pH value of 7.0 ± 2.0. The cocrys-
tal structure of SERCA complexed with thapsigargin (TG) was retrieved from the Protein Data Bank 
(PDB ID code 2AGV42). To prepare the protein for docking, the Protein Preparation Wizard module in 
Schrödinger 2009 was used. TMS was docked into the TG binding site of the SERCA using the Glide 
(Version 5.5, Schrödinger, LLC, New York, NY) with the standard precision (SP) scoring mode. The 
docking grid box was defined using the Receptor Grid Generation tool in Glide by centering on TG in 
the SERCA. In molecular docking, 5000 poses were generated during the initial phase of the docking 
calculation, out of which best 1000 poses were chosen for energy minimization by 1000 steps of con-
jugate gradient minimizations. The best binding pose for TMS was considered for the further analysis.
Molecular dynamic Simulations and binding free energy calculation. Molecular dynamic sim-
ulation was performed within AMBER1442. For each simulation, a sophisticated protocol including min-
imization, heating and equilibration was employed. Then, 15 ns MD simulation was conducted in NPT 
ensemble under a temperature of 310K and a pressure of 1 atm using a periodic boundary condition.
Binding free energy (∆ /GMM GBSA) of TMS and DMU-212 to SERCA excluding entropic contribution 
was calculated using the single-trajectory based MM/GBSA method43 and given by: 
∆ = ∆ + ∆ + ∆ + ∆/G E E G GMM GBSA vdW ele pol nonpol
Endogenous autophagy detection. The detection of endogenous LC3 was conducted using immu-
nofluorescence staining method as described previously17. In brief, TMS-treated cancer cells on cover 
slips were fixed with 4% paraformaldehyde (Sigma) for 20 min at room temperature and then rinsed 
with PBS. Immerse coverslips in methanol at room temperature for 2 min. After washing with PBS, the 
cells were then incubated with anti-LC3B (1:200) in TBST (100 mM Tris HCl, pH 7.5, 150 mM NaCl, 
0.05% Tween 20 and 5% BSA) overnight at 4 °C. After washing with PBS, the cells were incubated with 
anti-mouse secondary antibody (TRITC) 1:200 in TBST containing 5% BSA at 37 °C for 1 hr in the 
dark. The coverslips were then mounted with FluorSave™ mounting media (Calbiochem, San Diego, CA, 
USA) for fluorescence imaging and localization of LC3 autophagosomes were captured under the API 
Delta Vision Live-cell Imaging System (Applied Precision Inc., GE Healthcare Company, Washington, 
USA). To quantify autophagy, guidelines were followed to monitor autophagy23, the percentage of cells 
with punctuate LC3 immunofluorescence staining was calculated by counting the number of the cells 
showing the punctuate pattern of LC3 fluorescence (≥ 10 dots/cell) in immunofluorescence positive cells 
over the total number of cells in the same field. A minimum of 1000 cells from randomly selected fields 
were scored.
Measurement of intracellular calcium. Changes in intracellular free calcium were measured by a 
fluorescent dye, Fluo-3 as previously described44. Briefly, H1975 cells were washed twice with culture 
media after TMS treatment (40–80 nM) for 4 hr. Then cell suspensions were incubated with 5 μ M Fluo-3 
at 37 °C for 30 min. After the cells were washed twice with HBSS, the re-suspended cell samples were 
then subjected to FACS analysis. At least 10,000 events were analyzed.
The Measurement of SERCA Activity. Purified Ca2+ ATPase (SERCA1A) was prepared from female 
rabbit hind leg muscle45. ATPase activity was determined using the enzyme-coupled method utilizing 
pyruvate kinase and lactate dehydrogenase as previously described46. Porcine brain microsomes were 
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prepared as described before47. Due to the relatively low level of Ca2+ATPase activity in these micro-
somal membranes, the rate of Ca2+-dependent ATP hydrolysis were measured using the more sensitive 
phosphate liberation assay as described before48. All SERCA inhibition data were fitted to the allosteric 
dose versus effect equation using Fig P (Biosoft, Cambridge, UK).
Activity = minimum activity + (maximum activity‒minimum activity)/(1 + ([I]/IC 50) P).
Statistical analysis. All experiments were performed in triplicate. Data were expressed as the 
mean ± SEM. Differences were considered statistically significant at P < 0.05.
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